Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senju Pharmaceutical Co. Ltd.

www.senju.co.jp

Latest From Senju Pharmaceutical Co. Ltd.

Supreme Court Refuses Inter Partes Review

Standards of evidence for obviousness used in US inter partes patent reviews will not be reviewed by the US Supreme Court. Nor will the court consider whether the Federal Circuit can confirm inter partes decisions without issuing an opinion.

Intellectual Property Legal Issues

Supreme Court Seems Unconvinced USPTO Should Receive Attorneys' Fees In District Court Litigation

Justices question why it took 170 years for the patent office to seek attorneys' fees from patent applicants who challenge its decisions in district court; USPTO acknowledges the delay is 'atmospherically unhelpful.'

Legal Issues Intellectual Property

Top US Court Is Asked To Review Inter Partes Reviews

Standards for determining obviousness via inter partes patent reviews, as well as procedures for affirming such determinations on appeal, must be reviewed by the US Supreme Court, two originators argue in their dispute with Akorn over Durezol difluprednate eye drops.

 


Intellectual Property Legal Issues

Asia Deal Watch: Takeda On A Deal Spree

Takeda has inked three deals in recent days: a cancer antibody-drug conjugate partnership, a PI3K out-license and a nanomedicine drug-delivery pact. AstraZeneca gains expanded rights to Kyowa Hakko Kirin’s Fasenra.

Asia Pacific Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Senju Pharmaceutical Co. Ltd.
  • Senior Management
  • Yukoh Yoshida, Pres. & CEO
    Takashi Sugisawa, Exec. Officer, Head, Bus. Dev.
    Hidemi Shitaji, Exec. Officer, Head, R&D
  • Contact Info
  • Senju Pharmaceutical Co. Ltd.
    Phone: (81) 6 201 2512
    2-5-8,Hirano-machi
    Osaka, 541-0046
    Japan
UsernamePublicRestriction

Register